APDP - Associação Protectora dos Diabéticos de Portugal

Lisbon 1250-230

3 studies enrolling now · 16 studies all time

What they study most

Cardiovascular Diseases, Cardiovascular Risk, Chronic Kidney Disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Hypertension, Inflammation, Kidney Disease, Chronic, Non-alcoholic Steatohepatitis, Obesity, Overweight

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight — Starting soon
• A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes — Running, not enrolling
• Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) — Running, not enrolling
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) — Completed
• A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight — Withdrawn before enrolling
• A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight — Completed
• A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) — Completed
• AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Starting soon
• A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity — Running, not enrolling
• A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec — Completed
• A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease — Completed
• A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease — Completed
• Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) — Completed
• Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) — Completed